Tuncay GÜNDÜZ, Gonca ÖZCAN, Arman ÇAKAR, Halil İbrahim AKÇAY, Ayşe Nur ÖZDAĞ ACARLI, Mefküre ERAKSOY, Murat KÜRTÜNCÜ

Comparison of Mitoxantrone versus Cyclophosphamide Treatment in Patients with Secondary Progressive Multiple Sclerosis

Objective: Mitoxantrone (Mtx) and cyclophosphamide (Cyc) have successfully been used in highly aggressive multiple sclerosis (MS) patients. This study aims to compare the efficacy of these drugs in patients with secondary progressive MS (pwSPMS). Method: Clinical data of pwSPMS treated with either Mtx or Cyc were collected retrospectively. The EDSS scores before, during, and after the drug was determined. The efficacy of the drug was evaluated according to the EDSS change after the completion of therapy. The variations in clinical benefit between the two groups were investigated, as well as the factors that influenced them. Results: Fifty-nine SPMS patients (29 Mtx, 30 Cyc) were included in our study. Mean treatment periods were 19.5±9.9 months for Mtx and 9.1±4.1 months for the Cyc group. Mean EDSS in Mtx and Cyc groups at the first dose were 6.2±0.7 and 6.3±0.8, respectively (p=0.42). The percentage of patients who benefited from treatment was 41.6% in the Mtx group and 43.0% in the Cyc group (p=0.54). However, Mtx was more effective in patients with younger age of disease onset (p=0.01). Conclusion: Immunosuppression with intravenous Mtx and Cyc may equally prevent progression in patients with SPMS. Additionally, Mtx may be more beneficial in MS patients with earlier disease onset.

Keywords:

Mitoxantrone, Cyclophosphamide;, Multiple Sclerosis, Chronic Progressive; Alkylating Agents; Topoisomerase II Inhibitors,

PDF

___

1. Thompson AJ, Baranzini SE, Geurts J, et al. Multiple sclerosis. The Lancet. 2018;391:1622-36.
2. Filippi M, Preziosa P, Langdon D, et al. Identifying Progression in Multiple Sclerosis: New Perspectives. Ann Neurol. 2020;88:438-52.
3. Kavaliunas A, Manouchehrinia A, Stawiarz L, et al. Importance of early treatment initiation in the clinical course of multiple sclerosis. Multiple Sclerosis. 2017;23:1233-40.
4. Lizak N, Malpas CB, Sharmin S et al. Association of Sustained Immunotherapy With Disability Outcomes in Patients With Active Secondary Progressive Multiple Sclerosis. JAMA Neurol. 2020;77:1398-407.
5. Hamzehloo A, Etemadifar M. Mitoxantrone reduced disability in Iranian patients with multiple sclerosis. Arch Iran Med. 2007;10:59-64.
6. Krishnan C, Kaplin AI, Brodsky RA et al. Reduction of disease activity and disability with high-dose cyclophosphamide in patients with aggressive multiple sclerosis. Arch Neurol. 2008;65:1044-51.
7. Schwartzman RJ, Simpkins N, Alexander GM et al. High-dose cyclophosphamide in the treatment of multiple sclerosis. CNS Neurosci Ther. 2009;15:118- 27.
8. Scott LJ, Figgitt DP. Mitoxantrone: A review of its use in multiple sclerosis. CNS Drugs. 2004;18:379- 96.
9. Zipoli V, Portaccio E, Hakiki B, et al. Intravenous mitoxantrone and cyclophosphamide as second-line therapy in multiple sclerosis: An open-label comparative study of efficacy and safety. Journal of the Neurological Sciences. 2008;266:25-30.
10. Dendrou CA, Franklin RJM, Fugger L. The immunology and neurobiology of multiple sclerosis. Nature reviews immunology. 2016:2016-.
11. Lorscheider J, Buzzard K, Jokubaitis V, et al. Defining secondary progressive multiple sclerosis. Brain. 2016;139:2395-405.
12. Leray E, Yaouanq J, Le Page E, et al. Evidence for a two-stage disability progression in multiple sclerosis. Brain. 2010;133:1900-13.
13. Filippi M, Bar-Or A, Piehl F, et al. Multiple sclerosis. Nat Rev Dis Primers. 2018;4:43.
14. Hauser SL, Bar-Or A, Comi G, et al. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. N Engl J Med. 2017;376:221-34.
15. Scott LJ. Siponimod: A Review in Secondary Progressive Multiple Sclerosis. CNS Drugs. 2020;34:1191-200.
16. Montalban X, Hauser SL, Kappos L, et al. Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. N Engl J Med. 2017;376:209-20.
17. Okuda DT: Immunosuppressive treatments in multiple sclerosis, vol. 122, 1 edn: Elsevier B.V.; 2014.
18. Edan G, Miller D, Clanet M, et al. Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria. J Neurol Neurosurg Psychiatry. 1997;62:112-8.
19. Hartung HP, Gonsette R, König N, et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet. 2002;360:2018-25.
20. Edan G, Comi G, Le Page E, Leray E, Rocca MA, Filippi M. Mitoxantrone prior to interferon beta-1b in aggressive relapsing multiple sclerosis: a 3-year randomised trial. J Neurol Neurosurg Psychiatry. 2011;82:1344-50.
21. Le Page E, Edan G. Induction or escalation therapy for patients with multiple sclerosis? Rev Neurol (Paris). 2018;174:449-57.
22. Vollmer T, Panitch H, Bar-Or A, et al. Glatiramer acetate after induction therapy with mitoxantrone in relapsing multiple sclerosis. Mult Scler. 2008;14:663-70.
23. Aimard G, Girard PF, Raveau J. [Multiple sclerosis and the autoimmunization process. Treatment by antimitotics]. Lyon Med. 1966;215:345-52.
24. Patti F, Lo Fermo S. Lights and shadows of cyclophosphamide in the treatment of multiple sclerosis. Autoimmune Dis. 2011;2011:961702.
25. Stankiewicz JM, Kolb H, Karni A, Weiner HL. Role of Immunosuppressive Therapy for the Treatment of Multiple Sclerosis. Neurotherapeutics. 2013;10:77-88.
26. Brochet B, Deloire MS, Perez P et al. Double-Blind Controlled Randomized Trial of Cyclophosphamide versus Methylprednisolone in Secondary Progressive Multiple Sclerosis. PLoS One. 2017;12:e0168834.
27. Perini P, Calabrese M, Tiberio M, et al. Mitoxantrone versus cyclophosphamide in secondary-progressive multiple sclerosis: a comparative study. J Neurol. 2006;253:1034-40.
28. Prosperini L, Mancinelli CR, Solaro CM et al. Induction Versus Escalation in Multiple Sclerosis: A 10-Year Real World Study. Neurotherapeutics. 2020;17:994-1004.
29. Wawrzyniak S, Rzepinski L. Is there a new place for mitoxantrone in the treatment of multiple sclerosis? Neurol Neurochir Pol. 2020;54:54-61.
30. Harrison DM, Gladstone DE, Hammond E, et al. Treatment of relapsing-remitting multiple sclerosis with high-dose cyclophosphamide induction followed by glatiramer acetate maintenance. Mult Scler. 2012;18:202-9.
31. Spelman T, Magyari M, Piehl F, et al. Treatment Escalation vs Immediate Initiation of Highly Effective Treatment for Patients With Relapsing Remitting Multiple Sclerosis: Data From 2 Different National Strategies. JAMA Neurol. 2021.